The CE approval opens Europe for Cornerstone Robotics as the company expands its global surgical robotics business
Updated
May 29, 2026 4:20 AM
A tray of surgical tools. PHOTO: UNSPLASH
As surgical robotics companies expand beyond domestic markets, regulatory approvals are becoming a critical part of global growth. Companies are no longer competing only on hardware and clinical performance. They are also competing on their ability to enter tightly regulated healthcare systems and build long-term hospital partnerships.
Hong Kong-based Cornerstone Robotics is now moving further into that phase of expansion after its Sentire Endoscopic Surgical System received CE Mark certification under the European Union’s Medical Device Regulation framework.
The approval allows the company to commercialize the system across European markets for minimally invasive procedures in general surgery, gynecology, thoracic surgery and urology. For surgical robotics companies, regulatory approvals often represent more than product validation. They also determine market access, hospital adoption opportunities and long-term commercial scale.
Cornerstone Robotics has already been building clinical operations in the UK ahead of the approval. Since 2025, the company has worked with Portsmouth Hospitals University NHS Trust on clinical investigations involving the Sentire Surgical System. According to the company, the system has been used across procedures involving urology, gynecology and gastrointestinal surgery. The company says the clinical investigation helped generate real-world data to support physician training, research and future adoption efforts.
Alongside the regulatory approval, Cornerstone Robotics is also expanding its local operations in Europe. The company established a UK subsidiary in 2025 and has been developing training, clinical support and after-sales service capabilities for hospitals using the system.
That operational buildout reflects a larger challenge inside surgical robotics. Hospitals adopting robotic systems often require ongoing clinical training, technical support and workflow integration alongside the hardware itself.
Cornerstone Robotics says its strategy centers around vertically integrated development across engineering, software, imaging and robotics systems. The company argues that this structure gives it greater control over product development, supply chain management and long-term operational stability.
Professor Samuel Au, Founder and CEO of Cornerstone Robotics, said: "Receiving CE Certification marks a major milestone in Cornerstone Robotics' evolution from a technology innovator to a global clinical solutions provider. From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring high-quality surgical robotic solutions to more physicians and patients worldwide."
The CE approval also comes several months after the company completed an oversubscribed financing round of approximately US$200 million in November 2025.
The funding and regulatory expansion together signal how surgical robotics companies are increasingly entering a more commercially focused stage of growth. Beyond research and development, companies are now investing more heavily in regulatory approvals, hospital partnerships, physician training and international operational infrastructure as competition expands across global healthcare markets.
Keep Reading
Clinically grounded, game-based and always available — MIRDC’s AI system is redefining how children learn to communicate.
Updated
January 8, 2026 6:32 PM
A child practicing with a speech therapist. PHOTO: FREEPIK
Speech and language delays are common, yet access to therapy remains limited. In Taiwan, only about 2,200 licensed speech-language pathologists serve hundreds of thousands of children who need support—especially those with autism spectrum disorders or significant communication challenges. As a result, many children miss crucial periods of language development simply because help isn’t available soon enough.
MIRDC’s new AI-powered interactive speech therapy system aims to close that gap. Instead of focusing solely on articulation, it targets a wider range of language skills that many children struggle with: oral expression, comprehension, sentence building and conversational ability. This makes it a more complete tool for childhood speech and language development.
The system combines game-based learning, AI-driven guidance and automated language assessment into one platform that can be used both in clinics and at home. This integrated design helps children practice more consistently, providing therapists and parents with clearer insight into their progress.
The interactive game modules are built around clinically validated therapy methods. Imitation exercises, picture cards, storybooks and conversational prompts are turned into structured game levels, each aligned with a specific developmental goal. This step-by-step approach helps children move from simple naming tasks to more complex comprehension and response skills, all within a sequenced curriculum.
A key differentiator is the system’s real-time AI speech interpretation. As the child talks, the AI analyzes the response and generates tailored therapeutic cues—such as imitation, modeling, expansion or extension—based on the conversation. These are the same strategies used by speech-language pathologists, but now children can access them continuously, supporting more effective at-home practice and reducing long gaps between sessions.
After each session, the system automatically conducts a data-driven language assessment using 20 objective indicators across semantics, syntax and pragmatics. This provides clinicians and families with measurable, easy-to-understand reports that show how the child is progressing and which skills need more attention—something many traditional tools do not offer.
By offering a personalized, scalable and clinically grounded solution, MIRDC’s AI therapy system helps address the ongoing shortage of speech-language services. It doesn’t replace therapists; instead, it extends their reach, allows for more consistent practice and helps families support their child’s communication at home.
As an added recognition of its impact, the system recently earned two R&D 100 Awards, including the Silver Award for Corporate Social Responsibility. But at its core, the project remains focused on a simple mission: making high-quality speech therapy accessible to every child who needs a voice.